Funds increase stakes on Danish cancer company and are ready with new millions
The owners behind cancer treatment firm IO Biotech, three major Danish funds, have increased their stakes in the company with an investment of DKK 33.5m adding onto spring's capital injection. However, it's still far from the DKK 370m IO Biotech aimed to raise in 2018.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Biotech company IO Biotech's investors have so much faith in the management of the company – which develops drugs against cancer – that it's practically throwing money at the Copenhagen-based firm.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
IO Biotech gets DKK 60 million from funds
For abonnenter
